Perrigo announced last year that it wants to sell off its Generic Rx unit to better focus on its consumer business. The unit could sell for more than $2.5 billion, according to people familiar with the matter cited by Bloomberg.
Carlyle Group, Altaris Capital Partners and Cerberus Capital Management also advanced to the next round of bidding for the unit.
Apollo has been increasingly interested in healthcare assets, having purchased Brentwood, Tenn.-based LifePoint Health for $5.6 billion late last year.
Read the full report here.
More articles on pharmacy:
7 drugs projected to become blockbusters by 2023
3 insulin manufacturers to testify at House panel April 10
Cigna-Express Scripts cap out-of-pocket 30-day insulin costs at $25
